Statins: definitive translational research.
作者信息
Grundy Scott M
机构信息
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America Medical Service, Veterans Affairs Medical Center, Dallas, Texas, United States of America.
出版信息
Mol Med. 2014 Dec 16;20 Suppl 1(Suppl 1):S20-3. doi: 10.2119/molmed.2014.00194.
Abstract
摘要
相似文献
1
Statins: definitive translational research.他汀类药物：确定性的转化研究。
Mol Med. 2014 Dec 16;20 Suppl 1(Suppl 1):S20-3. doi: 10.2119/molmed.2014.00194.
2
Pleiotropic effects of statins: how important are they in the prevention of vascular disease?
Endothelium. 2003;10(1):3-4. doi: 10.1080/10623320303354.
3
The LDL receptor.低密度脂蛋白受体
Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):431-8. doi: 10.1161/ATVBAHA.108.179564.
4
Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation.他汀类药物可抑制氧化型低密度脂蛋白介导的凝集素样氧化型低密度脂蛋白受体-1（LOX-1）表达、氧化型低密度脂蛋白摄取以及蛋白激酶B（PKB）磷酸化水平的降低。
Cardiovasc Res. 2001 Oct;52(1):130-5. doi: 10.1016/s0008-6363(01)00371-6.
5
Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.糖基化与HMG-CoA还原酶抑制剂：对糖尿病及相关并发症的影响
Curr Diabetes Rev. 2019;15(3):213-223. doi: 10.2174/1573399814666180924113442.
6
Metabolic modes of action of the statins in the hyperlipoproteinemias.他汀类药物在高脂蛋白血症中的代谢作用模式。
Atherosclerosis. 1998 Dec;141(2):203-7. doi: 10.1016/s0021-9150(98)00198-1.
7
Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression.残粒样脂蛋白颗粒（RLP）与低密度脂蛋白（LDL）对 LDL 受体和 VLDL 受体的比较反应：大剂量他汀类药物对 VLDL 受体表达的影响。
Clin Chim Acta. 2012 Feb 18;413(3-4):441-7. doi: 10.1016/j.cca.2011.10.033. Epub 2011 Nov 7.
8
Brown and Goldstein: the cholesterol chronicles.布朗和戈尔茨坦：胆固醇编年史
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14829-32. doi: 10.1073/pnas.1315180110. Epub 2013 Aug 26.
9
The mystery of PCSK9.前蛋白转化酶枯草溶菌素9的奥秘。
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1337-9. doi: 10.1161/01.ATV.0000137288.82390.04.
10
Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte.他汀类药物、前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂与胆固醇稳态：肝细胞内视角
Clin Sci (Lond). 2017 May 1;131(9):791-797. doi: 10.1042/CS20160872.
引用本文的文献
1
Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.肥胖、血脂异常与心血管疾病：肥胖医学协会和国家脂质协会2024年联合专家综述
Obes Pillars. 2024 Mar 12;10:100108. doi: 10.1016/j.obpill.2024.100108. eCollection 2024 Jun.
2
Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?PCSK9 抑制剂和他汀类药物对胆固醇外排能力的影响：当前降脂治疗的局限性？
Eur J Clin Invest. 2022 Jul;52(7):e13766. doi: 10.1111/eci.13766. Epub 2022 Mar 24.
3
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制与他汀类药物对餐后富含甘油三酯脂蛋白代谢的影响比较。
Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1644-1655. doi: 10.1161/ATVBAHA.118.310882. Epub 2018 Jun 7.
本文引用的文献
1
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
2
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.一种针对 PCSK9 的单克隆抗体，REGN727/SAR236553，在他汀类药物稳定剂量治疗的杂合子家族性高胆固醇血症患者中，联合或不联合依折麦布治疗，降低低密度脂蛋白胆固醇：一项 2 期随机对照试验。
Lancet. 2012 Jul 7;380(9836):29-36. doi: 10.1016/S0140-6736(12)60771-5. Epub 2012 May 26.
3
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.辛伐他汀降低 LDL 胆固醇 5 年对 20536 名高危个体 11 年死亡率和发病率的影响：一项随机对照试验。
Lancet. 2011 Dec 10;378(9808):2013-2020. doi: 10.1016/S0140-6736(11)61125-2. Epub 2011 Nov 22.
4
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.辛伐他汀日剂量 80 毫克与 20 毫克对心肌梗死后 12064 例存活者的 LDL 胆固醇的强化降低作用：一项双盲随机试验。
Lancet. 2010 Nov 13;376(9753):1658-69. doi: 10.1016/S0140-6736(10)60310-8. Epub 2010 Nov 8.
5
The LDL receptor.低密度脂蛋白受体
Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):431-8. doi: 10.1161/ATVBAHA.108.179564.
6
PCSK9: a convertase that coordinates LDL catabolism.前蛋白转化酶枯草溶菌素9：一种协调低密度脂蛋白分解代谢的转化酶。
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S172-7. doi: 10.1194/jlr.R800091-JLR200. Epub 2008 Nov 19.
7
A gift from nature: the birth of the statins.自然的馈赠：他汀类药物的诞生。
Nat Med. 2008 Oct;14(10):1050-2. doi: 10.1038/nm1008-1050.
8
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.高剂量阿托伐他汀与常规剂量辛伐他汀用于心肌梗死后二级预防：IDEAL研究：一项随机对照试验。
JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437.
9
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.降低胆固醇治疗的疗效与安全性：对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
10
Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia.专题综述系列：动脉粥样硬化的发病机制：胆固醇争议的解读史，第三部分：从机制上界定高脂血症的作用
J Lipid Res. 2005 Oct;46(10):2037-51. doi: 10.1194/jlr.R500010-JLR200. Epub 2005 Jul 1.
Zotero 插件